Kv7 Channel Activators for Mutation-Linked Seizure Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodevelopmental disorders and developmental and epileptic encephalopathies, such as Angelman syndrome, Dravet syndrome, and KCNQ2-EE, are inadequate in addressing the underlying neuronal dysfunction caused by mutations in Kv7.2 and Kv7.3 channels, leading to severe developmental delays and treatment-resistant seizures.
Innovation Solution
Administration of Kv7 channel activators, such as N-(1-cyclobutyl-4-fluoro-6-(1-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3-dimethylbutanamide, to pediatric subjects, including fetuses and children, to enhance the function of Kv7.2 and Kv7.3 channels, thereby regulating neuronal excitability and improving developmental outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for neurodevelopmental disorders, then treatment resistance occurs, but the underlying neuronal dysfunction caused by mutations in Kv7.2 and Kv7.3 channels remains unaddressed
Solution Approach 1:
The patent introduces Kv7 channel activators as intermediary compounds that directly target and modulate the dysfunctional Kv7.2 and Kv7.3 channels. These compounds act as mediators between the mutated channels and normal neuronal function, restoring proper channel activity without requiring genetic correction. The activators bind to the channel proteins and enhance their opening probability, effectively bridging the functional gap created by mutations.
Solution Approach 2:
The invention changes the functional parameters of the Kv7 channels by administering activators that increase channel opening probability and duration. This pharmacological parameter change compensates for the defective channel kinetics caused by mutations, transforming the channels from a non-functional or hypofunctional state to a therapeutically effective state that can properly regulate neuronal excitability.
2Productivity
If conventional therapies are administered, then severe developmental delays persist, but no targeted mechanism addresses the specific channel mutations
Solution Approach 1:
The patent segments the broad category of neurodevelopmental disorders into specific subtypes caused by mutations in particular Kv7 channels (Kv7.2 and Kv7.3). This segmentation allows for targeted therapy development that addresses the specific molecular defect rather than treating all neurodevelopmental disorders with generic approaches, thereby improving developmental outcomes through mechanism-based treatment.
Solution Approach 2:
The Kv7 channel activators serve as specific intermediaries that bridge the gap between the identified genetic mutation and the desired therapeutic outcome. By targeting the specific channel protein product of the mutated genes, these compounds provide a direct mechanistic link between genotype and phenotype correction, enabling tailored interventions for patients with specific Kv7 channel mutations.
3Reliability
If Kv7 channel activators are administered to enhance channel function, then neuronal excitability is regulated, but achieving therapeutic effect in the presence of dominant-negative mutations remains challenging
Solution Approach 1:
The patent converts the harmful effect of dominant-negative mutations into a therapeutic opportunity by designing activators that can overcome the mutant channel's inhibitory effect. Rather than being blocked by the mutated channels, the activators are designed to bind with high affinity and force the channels into an open state, effectively using the mutant channels themselves as the target for correction rather than treating them as irreparable defects.
Solution Approach 2:
The activators dramatically change the functional parameters of the Kv7 channels, including increasing open probability from near-zero in mutant channels to therapeutically effective levels. This parameter transformation overcomes the dominant-negative effect by shifting the channel's operational characteristics from a non-functional state to one that can properly contribute to M-current and regulate neuronal excitability.
Data Source
AI summary
Provided herein are compounds and pharmaceutical compositions comprising a therapeutically effective amount of such compounds, or pharmaceutically acceptable salts, and a pharmaceutically acceptable excipient, and methods of treating neurodevelopmental diseases or disorders (NDD) and developmental and epileptic encephalopathy (DEE), comprising administering such compounds, or pharmaceutically acceptable salts, and pharmaceutical compositions, to pediatric patients.